Lipid Controls
Avanti Polar Lipids 18:0 CY5 PE 1MG
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(Cyanine 5)1MG
Cayman Chemical DLIn-MC2-DMA 1mg
An ionizable cationic lipid; has been used in the formation of LNPs; LNPs containing DLin-MC2-DMA and encapsulating siRNA targeting mRNA encoding FVII reduce hepatic levels of FVII in mice (ED50 = 0.6 mg/kg)
![Avanti Polar Lipids 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] (nickel salt), 231615-77-3, MFCD02259231, 25mg](https://assets.fishersci.com/TFS-Assets/CCG/product-images/VN00054318-11603-100G.JPG-250.jpg)
Avanti Polar Lipids 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl] (nickel salt), 231615-77-3, MFCD02259231, 25mg
Molecular Formula: C53H93N2O15Ni, Formula Weight: 1057.003, Storage Temperature: -20°C.
Avanti Polar Lipids 18:1 PI(3,4,5)P3
1,2-dioleoyl-sn-glycero-3-phospho-(1'-myo-inositol-3',4',5'-trisphosphate)
Avanti Polar Lipids 18:1 PI(3)P 1,2-DIOLEOYL-SN-G
3-phospho-(1'-myo-inositol-3'-phosphate) (ammonium
Medchemexpress LLC DSPE-PEG2000-Mal ammonium | 474922-22-0 | >99.9% | (C2H4O)nC51H92N1O13P.H3N | 25 MG
DSPE-PEG2000-Mal ammonium contains DSPE phospholipid and maleimide, designed for preparing nanostructured lipid carriers. It is known to extend blood circulation time and increase stability for encapsulated agents. Immune liposomes constructed with this product can be utilized for brain drug delivery.
- Contains DSPE phospholipid and maleimide
- Prepares nanostructured lipid carriers
- Extends blood circulation time
- Increases stability for encapsulated agents
- Can be used for brain drug delivery with immune liposomes
(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC#CC#CCCCCCCCCCC | 25mg | 718091956](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502474712.JPG-250.jpg)
eMolecules 84271-00-1 | PTPC | Broadpharm824.178 | C47H86NO8P | 0.000 | CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC#CC#CCCCCCCCCCC | 25mg | 718091956
PTPC | Broadpharm | 84271-00-1824.178 | C47H86NO8P | 0.000 | CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC#CC#CCCCCCCCCCC | 25mg | 718091956
Avanti Polar Lipids 18:1 PI(3,4)P2 1,2-DIOLEOYL-SN
18:1 PI(3,4)P2 1,2-dioleoyl-sn-glycero-3-phospho-(1'-myo-inositol-3',4'-bisphosphate) (ammonium salt) 100ug
Apexbio Technology LLC DLIN-KC2-DMA-10MG
DLin-KC2-DMA (CAS No 1190197-97-7) is a lipid-based nanoparticle formulation commonly used in the field of biomedical research particularly in the delivery of nucleic acids for gene therapy and RNA interference Originating from advancements in lipid nanoparticle technology it functions by encapsulating therapeutic nucleic acids facilitating their cellular uptake and endosomal escape This enables effective delivery into target cells enhancing gene silencing or expression DLin-KC2-DMA exhibits potent activity in vitro typically in the nanomolar to low micromolar range allowing it to be a versatile tool in drug development and screening Its applications extend to various cell models including primary and immortalized cell lines as well as in vivo animal studies where it aids in the evaluation of gene delivery efficacy and safety Experimental concentrations typically depend on the specific research design to ensure optimal results within each study s context